Program
Risperidone
Also written as “risperidone”, “Oral risperidone” and “Risperidone ISM 100 mg”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Psychotic Disorders · Autistic Disorder · Dementia, led by 15 companies.
Drug pageRisperidone: every studyMany companies study it; this page follows only the 99 they lead. All 262 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 670 open or running | phase 4since Jun 4, 2003 | May 2, 2002 | none ahead |
| Rovi Pharmaceuticals Laboratoriesits history only | 50 open or running | phase 3since May 12, 2017 | Feb 5, 2013 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 3since Apr 9, 2018 | Jan 26, 2009 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 4since Nov 14, 2005 | May 2, 2002 | none ahead |
| Luye Pharma Groupits history only | 30 open or running | phase 1since Jan 31, 2014 | Jan 31, 2014 | none ahead |
| Lyndraits history only | 30 open or running | phase 3since Mar 9, 2023 | Sep 16, 2020 | none ahead |
| Braeburn Pharmaceuticalsits history only | 20 open or running | phase 3since May 11, 2016 | Jan 7, 2016 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Feb 4, 2010 | Feb 4, 2010 | none ahead |
| IPCA Laboratoriesits history only | 20 open or running | phase 1since Jun 11, 2012 | Jun 11, 2012 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | no phasesince Oct 15, 2010 | Oct 15, 2010 | none ahead |
| Torrent Pharmaceuticalsits history only | 20 open or running | phase 1since Jul 10, 2009 | Jul 10, 2009 | none ahead |
| Delporits history only | 10 open or running | phase 2since Jun 1, 2020 | Jun 1, 2020 | none ahead |
| Indivior Pharmaceuticalsits history only | 10 open or running | phase 4since May 30, 2019 | May 30, 2019 | none ahead |
| Pfizerits history only | 10 open or running | no phasesince Sep 9, 2005 | Sep 9, 2005 | none ahead |
| Yung Shin Pharm. Ind.its history only | 10 open or running | phase 2since Oct 23, 2023 | Oct 23, 2023 | none ahead |
Also a collaborator on its studies: Otsuka and H. Lundbeck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Nov 10, 2005.
- Jul 14, 2017Phase 1 study in HealthyJohnson & Johnson · NCT03220867 · China
- Apr 9, 2018Phase 3 study in SchizophreniaTeva Pharmaceutical Industries · NCT03503318 · 544 enrolled · United States, Bulgaria
- May 4, 2018Phase 1 study in SchizophreniaRovi Pharmaceuticals Laboratories · NCT03527186 · 81 enrolled · United States
- Oct 18, 2018Phase 4 study in SchizophreniaJohnson & Johnson · NCT03713658 · 34 enrolled · Rwanda
- Feb 26, 2019Phase 3 study in SchizophreniaRovi Pharmaceuticals Laboratories · NCT03870880 · 215 enrolled · United States, Ukraine
- Mar 27, 2019Phase 3 study in SchizophreniaTeva Pharmaceutical Industries · NCT03893825 · 336 enrolled · United States, Bulgaria, Canada and more
- May 30, 2019Indivior Pharmaceuticals’ first study: phase 4 study in SchizophreniaNew to Indivior PharmaceuticalsIndivior Pharmaceuticals · NCT03978832 · 69 enrolled · United States
- Jun 1, 2020Delpor’s first study: phase 2 study in SchizophreniaNew to DelporDelpor · NCT04418466 · 34 enrolled · United States
- Sep 16, 2020Lyndra’s first study: phase 2 study in Psychotic DisordersNew to LyndraLyndra · NCT04567524 · 34 enrolled · United States
- Jun 22, 2021Phase 4 study in SchizophreniaJohnson & Johnson · NCT04940039 · 93 enrolled · Rwanda
- Dec 16, 2021Phase 1 study in SchizophreniaRovi Pharmaceuticals Laboratories · NCT05179525 · 80 enrolled · United States
- Mar 9, 2023Phase 3 study in SchizophreniaLyndra · NCT05779241 · 83 enrolled · United States
- Oct 23, 2023Yung Shin Pharm. Ind.’s first study: phase 2 study in Hot FlashesNew to Yung Shin Pharm. Ind.Yung Shin Pharm. Ind. · NCT06161792 · 10 enrolled · Taiwan
- Feb 25, 2025Phase 3 study in SchizophreniaLyndra · NCT06878833
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
Studies
The newest 60 of 99 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06878833Schizophrenia | 3 | Withdrawn | Lyndra | Dec 31, 2026 | 0 |
| NCT06161792Hot Flashes · Taiwan | 2 | Terminated | Yung Shin Pharm. Ind. | Mar 14, 2022 | 10 |
| NCT05779241Schizophrenia · United States | 3 | Completed | Lyndra | Nov 3, 2023 | 83 |
| NCT05179525Schizophrenia · United States | 1 | Completed | Rovi Pharmaceuticals Laboratories | Sep 17, 2021 | 80 |
| NCT04940039Schizophrenia · Rwanda | 4 | Completed | Johnson & Johnson | Apr 16, 2024 | 93 |
| NCT04567524Psychotic Disorders · United States | 2 | Completed | Lyndra | Dec 22, 2020 | 34 |
| NCT04418466Schizophrenia · United States | 2 | Completed | Delpor | Feb 10, 2023 | 34 |
| NCT03978832Schizophrenia · United States | 4 | Completed | Indivior Pharmaceuticals | May 12, 2020 | 69 |
| NCT03893825Schizophrenia · United States, Bulgaria, Canada and more | 3 | Completed | Teva Pharmaceutical Industries | Dec 2, 2021 | 336 |
| NCT03870880Schizophrenia · United States, Ukraine | 3 | Completed | Rovi Pharmaceuticals Laboratories | Jan 8, 2020 | 215 |
| NCT03713658Schizophrenia · Rwanda | 4 | Completed | Johnson & Johnson | Dec 2, 2019 | 34 |
| NCT03527186Schizophrenia · United States | 1 | Completed | Rovi Pharmaceuticals Laboratories | Mar 23, 2019 | 81 |
| NCT03503318Schizophrenia · United States, Bulgaria | 3 | Completed | Teva Pharmaceutical Industries | Sep 30, 2020 | 544 |
| NCT03220867Healthy · China | 1 | Withdrawn | Johnson & Johnson | Jan 2, 2018 | 0 |
| NCT03160521Acute Schizophrenia · United States, Ukraine | 3 | Completed | Rovi Pharmaceuticals Laboratories | Dec 17, 2018 | 438 |
| NCT02773576Schizophrenia · United States | 3 | Completed | Braeburn Pharmaceuticals | Sep 2017 | 140 |
| NCT02658357Schizophrenia · United States | 2 | Completed | Braeburn Pharmaceuticals | Aug 2017 | 66 |
| NCT02634463Immunoassay · Belgium | 1 | Completed | Johnson & Johnson | Nov 9, 2016 | 81 |
| NCT02462473Schizophrenia · United States | 2 | Terminated | Johnson & Johnson | Jan 2016 | 9 |
| NCT02186769Schizophrenia · United States | 1 | Completed | Luye Pharma Group | Apr 2015 | 16 |
| NCT02091388Schizophrenia · United States | 1 | Completed | Luye Pharma Group | Jan 2015 | 108 |
| NCT02087579Psychotic Disorders · United States, Argentina, Belgium and more | 1 | Completed | Johnson & Johnson | Oct 2014 | 305 |
| NCT02055287Schizophrenia · United States | 1 | Completed | Luye Pharma Group | Jun 2014 | 36 |
| NCT01855074Schizophrenia | 4 | Completed | Johnson & Johnson | Feb 2009 | 80 |
| NCT01788774Schizophrenia · Croatia, Russian Federation, South Africa and more | 1 | Completed | Rovi Pharmaceuticals Laboratories | Feb 2014 | 36 |
| NCT01726335Schizophrenia · Brazil | 4 | Completed | Johnson & Johnson | Mar 2008 | 53 |
| NCT01722201Fasting · India | 1 | Completed | IPCA Laboratories | Sep 2012 | 48 |
| NCT01624675Autistic Disorder · Japan | 3 | Completed | Johnson & Johnson | Oct 2014 | 39 |
| NCT01618760Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | IPCA Laboratories | Jun 2012 | 48 |
| NCT01607762Healthy · Belgium | 1 | Completed | Johnson & Johnson | Apr 2012 | 31 |
| NCT01222975Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Oct 2004 | 44 |
| NCT01222923Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Oct 2004 | 40 |
| NCT01064271Healthy | 1 | Completed | Dr. Reddy's Laboratories | Oct 2006 | 26 |
| NCT01064232Healthy | 1 | Completed | Dr. Reddy's Laboratories | Oct 2006 | 30 |
| NCT01050582Schizophrenia · United States, Belgium, Germany and more | 4 | Completed | Johnson & Johnson | Jul 2011 | 244 |
| NCT00992407Schizophrenia · Korea, Republic of | 4 | Completed | Johnson & Johnson | Dec 2010 | 75 |
| NCT00986336Bipolar Disorder | 1 | Completed | Johnson & Johnson | 56 | |
| NCT00939926Healthy · India | 1 | Completed | Torrent Pharmaceuticals | ||
| NCT00939497Healthy · India | 1 | Completed | Torrent Pharmaceuticals | ||
| NCT00934635Schizophrenia · Germany | 4 | Terminated | Johnson & Johnson | Dec 2009 | 2 |
| NCT00830349Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Jul 2001 | 30 |
| NCT00829894Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Jul 2001 | 24 |
| NCT00645502Schizophrenia | 1 | Completed | Johnson & Johnson | 40 | |
| NCT00576732Autistic Disorder · United States | 4 | Completed | Johnson & Johnson | Sep 2009 | 96 |
| NCT00558298Schizophrenia | 3 | Completed | Johnson & Johnson | 811 | |
| NCT00535132Schizophrenia · United States, Argentina, Colombia and more | 4 | Completed | Johnson & Johnson | Jul 2008 | 201 |
| NCT00526877Schizophrenia · Taiwan | 4 | Completed | Johnson & Johnson | Jan 31, 2009 | 31 |
| NCT00495118Schizophrenia | 3 | Completed | Johnson & Johnson | 314 | |
| NCT00378183Psychotic Disorders | 4 | Completed | Johnson & Johnson | 120 | |
| NCT00378092Schizophrenia · South Africa | 4 | Completed | Johnson & Johnson | Mar 2010 | 33 |
| NCT00305422Schizophrenia · Germany | 3 | Completed | AstraZeneca | 45 | |
| NCT00287742Alzheimer Disease | 3 | Terminated | Johnson & Johnson | 33 | |
| NCT00266552Conduct Disorder | 3 | Completed | Johnson & Johnson | 118 | |
| NCT00261508Autistic Disorder | 3 | Completed | Johnson & Johnson | 80 | |
| NCT00257075Bipolar Disorder | 3 | Completed | Johnson & Johnson | 267 | |
| NCT00254930Learning Disabilities | 3 | Completed | Johnson & Johnson | 19 | |
| NCT00254241Schizophrenia · United Kingdom | 4 | Completed | AstraZeneca | 80 | |
| NCT00253162Bipolar Disorder | 3 | Completed | Johnson & Johnson | 439 | |
| NCT00253149Bipolar Disorder | 3 | Completed | Johnson & Johnson | 158 | |
| NCT00253136Schizophrenia | 3 | Completed | Johnson & Johnson | 458 |
How it is read
Names in the registry
- “risperidone”, 40 entries
- “Risperidone”, 34 entries
- “Oral risperidone”, 5 entries
- “Risperidone ISM 100 mg”, 3 entries
- “LY03004”, 3 entries
Codes read as this program: LYN005.
Conditions, from the studies’ own filings
- Schizophrenia, 63 studies
- Bipolar Disorder, 12 studies
- Psychotic Disorders, 3 studies
- Autistic Disorder, 3 studies
- Dementia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.